Breaking News
CODEX 9/11 
Third Time's The Charm: SpaceX Starship Megarocket Blasts Off From Starbase
First Ever: Technocracy Roundtable Streaming Today
Comcast Network Horror: Summer Ratings Crash 49%, Advertisers In Major Bind
Top Tech News
Magnetic Fields Reshape the Movement of Sound Waves in a Stunning Discovery
There are studies that have shown that there is a peptide that can completely regenerate nerves
HERE COMES THE MOTHERSHIP
Swedish startup unveils Starlink alternative - that Musk can't switch off
Video Games At 30,000 Feet? Starlink's Airline Rollout Is Making It Reality
Automating Pregnancy through Robot Surrogates
SpaceX launches Space Force's X-37B space plane on 8th mystery mission (video)
This New Bionic Knee Is Changing the Game for Lower Leg Amputees
Grok 4 Vending Machine Win, Stealth Grok 4 coding Leading to Possible AGI with Grok 5
Venus Aerospace Hypersonic Engine Breakthroughs
DARPA Nucleic Technology Funded to Get Virus Response to 1-60 Days
The P3 teams are developing technologies to deliver antibodies using nucleic acid technology, and achieve sufficient serum concentrations of the antibodies for protection against the pathogen within three days after administration.
DARPA has programs for Pandemic Prevention Platform, Nucleic Acids On-Demand Worldwide (NOW), and PReemptive Expression of Protective Alleles and Response Elements (PREPARE) programs.
Nucleic Acids On-Demand Worldwide (NOW)
The goal of the NOW program is to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA) in less than 24 hours. The developed platform should be a resilient, mobile, readily accessible nucleic acid MCM manufacturing capability that enables immediate threat response anywhere the military operates with minimal user intervention.